• CD4 T-Cell mRNA Vaccines Drive Durable Antitumor Immunity

  2026-09-23

  Cho et al. reported that CD4 T cells engineered with both CD80 and 4-1BBL mRNAs stimulated stronger CD8 T-cell responses and antitumor effects than cells expressing either ligand alone. The poster suggests that expanded CD4 T cells can serve as an alternative cellular vaccine platform, while its abstract-level methods and distinct costimulatory pathway limit how directly the findings transfer to other mRNA constructs.

• Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance

  2026-09-23

  The reference study developed tumor-microenvironment pH-responsive nanoparticles for systemic PTEN mRNA delivery in trastuzumab-resistant breast cancer. By restoring PTEN expression and inhibiting PI3K/Akt signaling, the platform improved trastuzumab responsiveness while illustrating how formulation design can address both circulation and intracellular delivery barriers.

• Alternariol: From Exposure Signal to Fibrosis Phenotype

  2026-09-22

  Alternariol (AOH) is more than a foodborne mycotoxin: it is a model compound for connecting metabolic activation, cell injury, and hepatic stellate-cell remodeling. This article presents a phenotype-to-pathway framework for designing and interpreting advanced AOH experiments.

• BX795: PDK1 Inhibition Meets TBK1 Biology

  2026-09-22

  BX795 is a PDK1 inhibitor with additional TBK1 and IKKε activity, making it a valuable probe for connecting kinase signaling, cancer cell growth inhibition, and innate immune response modulation. This article explains how recent HBV research changes the way BX795 should be deployed and interpreted in mechanistic assays.

• Geneticin, G-418 Sulfate: Selection Guide

  2026-09-21

  Geneticin, G-418 Sulfate (G418 Sulfate) provides an aqueous aminoglycoside selection reagent for enriching cells that express the neomycin resistance gene and for controlled antiviral experiments. This guide explains stock preparation, selection setup, and controls while limiting Dengue virus inhibition claims to the reported BHK-cell context rather than treating the product dossier as universal validation.

• AM251: From CB1 Receptor Antagonism to Translation

  2026-09-21

  AM251 is a potent CB1 receptor antagonist that helps translational researchers separate cannabinoid receptor signaling from downstream and off-target effects. This thought-leadership guide connects mechanistic pain biology, experimental validation, metabolic research, apoptosis assays, and strategic study design.

• Brefeldin A Workflows for ER–Golgi Stress Studies

  2026-09-20

  Brefeldin A converts ER–Golgi trafficking disruption into a measurable workflow for secretion, organelle morphology, ER stress, and cancer-cell assays. This guide combines practical BFA dosing with controls that help distinguish trafficking-specific effects from nonspecific cytotoxicity.

• Octenidine dihydrochloride: Assay Workflows

  2026-09-19

  Build more reproducible membrane-disruption, susceptibility, and biofilm assays with Octenidine dihydrochloride. This guide combines practical formulation advice with reference-backed comparisons, controls, and troubleshooting for antimicrobial research.

• Brefeldin A Workflows for ER Stress Research

  2026-09-18

  Use Brefeldin A as a controlled trafficking perturbation to connect ER-to-Golgi transport failure with ER stress, secretion defects, and cell death. This practical guide combines dose and timing design with UBR1/UBR2-focused assays and cancer-cell troubleshooting.

• 10074-G5: A c-Myc Inhibitor Workflow

  2026-09-18

  Build a mechanism-first cancer research workflow around 10074-G5, linking c-Myc/Max disruption to apoptosis, cell cycle arrest, and EMT reversal. The approach is especially useful for testing the miR-196a–c-Myc–TERT–NFκB axis in esophageal adenocarcinoma while preserving orthogonal controls and practical troubleshooting.

• Brefeldin A: ER Stress Workflow & Cell Assays

  2026-09-17

  Brefeldin A converts ER-to-Golgi trafficking disruption into a practical platform for studying secretion, ER stress, and cancer-cell fate. This guide links dose–time design with trafficking, apoptosis, migration, and protein-quality-control readouts while highlighting controls that prevent cytotoxicity from being mistaken for mechanism.

• Total RNA Extraction Reagent in Ferroptosis Studies

  2026-09-17

  Total RNA Extraction Reagent (Trizol) supports reproducible transcript analysis in radiation-oncology research. This article explains how RNA isolation choices shape interpretation of DHODH, ferroptosis, and macrophage-polarization findings after carbon-ion radiotherapy.

• SW033291: A 15-PGDH Assay Strategy

  2026-09-16

  SW033291 is a potent 15-PGDH inhibitor for dissecting prostaglandin E2 elevation across biochemical, cellular, hematopoietic, and regenerative models. This article presents an assay-centered framework that separates target engagement from tissue-level outcomes and clarifies how recent muscle-repair findings should guide experimental design.

• Biotin-HPDP: Reversible Thiol Labeling Guide

  2026-09-16

  Biotin-HPDP is a sulfhydryl-reactive biotinylation reagent for selective, reversible labeling of accessible thiols. Its pyridyl disulfide chemistry supports thiol-specific protein labeling, streptavidin-based detection, affinity purification, and controlled release with reducing agents.

• Brefeldin A Workflows for ER Stress Research

  2026-09-15

  Brefeldin A converts a trafficking perturbation into a practical way to study ER stress, secretion defects, and cell-fate decisions in parallel. This workflow shows how BFA can distinguish transport-dependent phenotypes from downstream apoptosis while improving assay reproducibility in cancer and cell-biology models.

8571 records 1/572 page Next 12345 下5页 Last page